Rznomics Inc. (KR)

https://www.rznomics.com

Rznomics is a biopharmaceutical company founded in 2017 dedicated to the development of gene therapies for cancers, degenerative diseases, and genetic diseases based on cutting-edge RNA technology. Core platform technology of Rznomics is based on RNA replacement enzyme called ‘trans-splicing ribozyme’, which can edit target RNAs via simultaneous destruction and repair (and/or reprograming) to yield the desired therapeutic RNAs, thus selectively inducing therapeutic gene activity in cells expressing the target RNAs. Rznomics has developed and optimized the ribozymes to be applied as therapeutics for intractable human disease by developing them to have high target specificity and efficacy, target accuracy and minimal off-target ability. Rznomics has established pipelines targeting indications with high unmet medical demand for which the unique properties of the ribozymes can be the most competitive. The leading candidate is treatment for hepatocellular carcinoma, and treatments for glioblastoma, Alzheimer’s disease and hereditary retinal dystrophy are also under development. *

	Start	2017-08-29 established (s-off
	Industry	gene therapy
	Industry 2	RNA-based therapeutic
	Person	Lee, Seong-Wook (Rznomics 202010 CEO + Founder + Prof at Donkook Univ)

	City	n. a.
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Cevec Pharmaceuticals GmbH. (10/19/20). "Press Release: Cevec and Rznomics Sign License Agreement for the Use of CAP® Technology in Manufacturing of Adenoviral Vectors".

		Record changed: 2020-10-27

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Rznomics Inc. (KR)

[1] Cevec Pharmaceuticals GmbH. (10/19/20). "Press Release: Cevec and Rznomics Sign License Agreement for the Use of CAP® Technology in Manufacturing of Adenoviral Vectors"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)